17-PA
- Product Name
- 17-PA
- CAS No.
- 694438-95-4
- Chemical Name
- 17-PA
- Synonyms
- 17-PA;17PA,17 PA;17-Phenyl-(3α,5α)-androst-16-en-3-ol;17-PHENYL-(3A,5A)-ANDROST-16-EN-3-OL;17-Phenyl-(3α,5α)-androst-16-en-3-ol;Androst-16-en-3-ol, 17-phenyl-, (3α,5α)-
- CBNumber
- CB52453436
- Molecular Formula
- C25H34O
- Formula Weight
- 350.54
- MOL File
- 694438-95-4.mol
17-PA Property
- storage temp.
- Store at RT
- solubility
- <8.76mg/ml in DMSO; <17.53mg/ml in ethanol
N-Bromosuccinimide Price
- Product number
- 2681
- Product name
- 17-PA
- Purity
- ≥99%(HPLC)
- Packaging
- 10
- Price
- $217
- Updated
- 2021/12/16
- Product number
- 2681
- Product name
- 17-PA
- Purity
- ≥99%(HPLC)
- Packaging
- 50
- Price
- $870
- Updated
- 2021/12/16
- Product number
- 254348
- Product name
- 17-PA
- Packaging
- 10mg
- Price
- $579
- Updated
- 2021/12/16
- Product number
- P133880
- Product name
- 17-PA
- Packaging
- 25mg
- Price
- $365
- Updated
- 2021/12/16
- Product number
- B7151
- Product name
- 17-PA
- Packaging
- 10mg
- Price
- $408
- Updated
- 2021/12/16
17-PA Chemical Properties,Usage,Production
Uses
17-PA is an antagonist of neurosteroid GABA potentiation.
Biological Activity
Selective antagonist of neurosteroid potentiation and direct gating of GABA A receptors. Selectively reduces the effects of 5 α -reduced steroids compared to 5 β -reduced steroids and displays no effect on potentiation evoked by barbiturates and benzodiazepines. Attenuates 3 α ,5 α -THP-induced loss of righting reflex and total sleep time following i.c.v administration in rats.
Enzyme inhibitor
This selective neurosteroid antagonist (FW = 350.54 g/mol; CAS 694438- 95-4; Soluble to 25 mM in DMSO and to 50 mM in ethanol), also known as 17-PA, targets neurosteroid potentiation and directly gates GABAA receptors. 17-PA inhibition was also useful in demonstrating that ethanol modulates the interaction of the endogenous neurosteroid allopregnanolone with the α1β2γ2L GABAA receptor. 17-PA selectively reduces the effects of 5α-reduced steroids compared to 5β-reduced steroids and displays no effect on potentiation evoked by barbiturates and benzodiazepines. It also attenuates 3α,5α-THP-induced loss of righting reflex and total sleep time, following intracerebroventricular administration in rats.